NCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT06100874 2026-02-24
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04639986 2026-02-09
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Gilead Sciences
Phase 3 Active not recruiting
NCT04454437 2026-02-02
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Gilead Sciences
Phase 2 Active not recruiting
NCT04448886 2026-01-15
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06612203 2025-12-05
WIN-B
MedSIR
Phase 1/2 Active not recruiting
NCT04595565 2025-11-25
SASCIA
GBG Forschungs GmbH
Phase 3 Active not recruiting
NCT05675579 2025-11-04
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05143229 2025-10-06
ASSET
University of Kansas Medical Center
Phase 1 Active not recruiting
NCT05840211 2025-10-03
ASCENT-07
Gilead Sciences
Phase 3 Active not recruiting
NCT05382299 2025-09-05
ASCENT-03
Gilead Sciences
Phase 3 Active not recruiting
NCT05101096 2025-03-25
ASCENT-J02
Gilead Sciences
Phase 1/2 Active not recruiting